Shire blasts Roche over its 'mis­lead­ing' case for trail­blaz­ing he­mo­phil­ia drug emi­cizum­ab, scor­ing in­junc­tion

Over the past year, Shire $SH­PG has seen its shares buf­fet­ed re­peat­ed­ly as Roche moved steadi­ly ahead with its late-stage pro­gram for its close­ly-watched he­mo­phil­ia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER